Antihistamines: a review

No. 5 H1 Antihistamines: a review 311
48. Brannan MD, Reidenberg P, Radwanski E, Shneyer
L, Lin CC, Cayen MN, et al. Loratadine administered
concomitantly with erythromycin: pharmacokinetic
and electrocardiographic evaluations. Clin
Pharmacol Ther 1995; 58: 269-278.
49. Delgado LF, Pferferman A, Sole D, Naspitz CK.
Evaluation of the potential cardiotoxicity of the
antihistamines terfenadine, astemizol, loratadine,
and cetirizine in atopic children. Ann Allergy Asthma
Immunol 1998; 80: 333-337.
50. Ducic I, Ko CM, Shuba Y, Morad M. Comparative
effects of loratadine and terfenadine on cardiac
K+ channels. J Cardiovasc Pharmacol 1997; 30:
42-54.
51. Lindquist M, Edwards IR. Risks of non-sedating
antihistamines. Lancet 1997; 349: 1322.
52. Lacerda AE, Roy ML, Lewis EW, Rampe D. Interactions
of the nonsedating antihistamine loratadine
with a Kv1.5-type potassium channel cloned from
human heart. Mol Pharmacol 1997; 52: 314-322.
53. Pratt CM, Hertz RP, Ellis BE, et al. Risk of developing
life-threatening ventricular arrhytmia associated
with terfenadine in comparison with overthe-counter
antihistamines, ibuprofen and
clemastine. Am J Cardiol 1994; 73: 346-352.
54. Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski
RF, Guinosso PJ, Lynch JJ. Cardiac electrophysiological
actions of the histamine H1 receptor antagonists
astemizole and terfenadine compared with
clorpheniramine and pyrilamine. Circ Res 1995;
76: 110-119.
55. Schuller DE. Adverse effects of brompheniramine
on pulmonary function in a subset of asthmatic
children. J Allergy Clin Immunol 1983; 72: 175-
179.
56. American Academy of Allergy and Immunology:
The use of antihistamines in patients with asthma.
J Allergy Clin Immunol 1988; 82: 481-482.
57. Babe KS, Serafin WE. Histamina, bradicinina y sus
antagonistas. En: Goodman and Gilman. Las bases
farmacol—gicas de la terapŽutica, 8» ed. esp. Mexico
DF: McGraw-Hill Interamericana, 1996.
58. Barbanoj MJ, Antonijoan RM, Garc’a-Gea C, Massana
E, JanŽ F. Bases neurobioqu’micas del efecto
central de los antihistam’nicos. En: çlvarez FJ, del
R’o MC. Antihistam’nicos H1 y conducci—n de
veh’culos. Barcelona: (Coord.) Masson SA, 1998.
59. Miranda P‡ez A. Tipos de antihistam’nicos. Mesa
redonda "Antihistam’nicos". III Reuni—n Conjunta
Societat Catalana d'Al-l rgia/Alerg—logos e Inmun—logos
del Sur. Barcelona, 1987.
60. Rietschel RL, Fowler JF. Contact Photodermatitis.
En: Fischer«s Contact Dermatitis. 4» ed. Cap’tulo
23. Baltimore: Williams and Wilkins, 1995.
61. Rossoni G, Omini C, Folco GC, Vigano T, Brunelli
G, Berti F. Bronchodilating activity of mequitazine.
Arch Int Pharmacodyn Ther 1984; 268: 128.
62. Gamboa PM, Oehling A. Ketotifeno. Su acci—n en
las enfermedades alŽrgicas. Barcelona: Laboratorios
Sandoz, 1988.
63. Patella V, de Crescenzo G, Marino O, Spadaro G,
Genovese A, Marone G. Oxatomide inhibits the
release of proinflammatory mediators from human
basophils and mast cells. Int Arch Allergy Immunol
1996; 111: 23-29.
64. Van Nueten JM, Xhonneux R, Janssen PAJ. Preliminary
data on antiserotonin effects of oxatomide,
a novel antiallergic compound. Arch Int Pharmacodyn
Ther 1978; 232: 217.
65. Ohmori K, Manabe H, Akuta-Ohnuma K. Inhibitory
effect of oxatomide on oxygen-radical generation
and peptide-leukotriene release from guinea-pig
eosinophils. Arzneimittelforschung 1998; 48: 43-46.
66. Noma T, Yoshizawa I, Kawano Y, Nakajima T.
Effect of oxatomide on T-cell activation and the
production of interferon-gamma in mite sensitive
asthma. Eur J Pharmacol 1998; 343: 239-247.
67. Connel JT, Perhach JL, Weiler JM, Rosenthal R,
Hamilton L, Diamond L, et al. Azelastine (AZ), a
new antiallergy agent: efficacy in ragweed hay
fever. Ann Allergy 1985; 55: 392.
68. McTavish D, Sorkin EM. Azelastine: a review of its
pharmacodynamic and pharmacokinetic properties,
and therapeutic potential. Drugs 1989; 38: 778-800.
69. Spaeth J, Schultze V, Klimek L, Lengersdorf A,
Mšsges R. Azelastine reduces histamine-induced
swelling of nasal mucosa. ORL 1996; 58: 157-163.
70. AntŽpara I, J‡uregui I, Basomba A, et al. Investigaci—n
de la eficacia y tolerabilidad de azelastina
spray nasal 'versus' ebastina comprimidos en
pacientes con rinitis alŽrgica estacional. Allergol
Immunopathol 1998; 26: 1-8.
71. Dechant KL, Goa KL. Levocabastine: a review of
its pharmacological properties, and therapeutic
potential as a topical antihistamine in allergic rhinitis
and conjunctivitis. Drugs 1991; 41: 202-224.
72. Mšsges R, Spaeth J, Klimek L. Eficacia y tolerabilidad
de levocabastina y azelastina en spray nasal
para el tratamiento de la rinitis alŽrgica. Mediators
Inflammation 1995, 4: S11-S15.
73. The Livostin Study Group. A comparison of topical
levocabastine and oral terfenadine in the treatment
of allergic rhinoconjunctivitis. Allergy 1993; 48:
519-524.
74. The Swedish GP Allergy Team. Topical levocabastine
compared with oral loratadine for the treatment
of seasonal allergic rhinoconjunctivitis. Allergy
1994; 49: 611-615.